Observational studies at the SCAI meeting favored the dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) over ...

The US guidelines are likely to change following the release of the VANISH2 results last year, Christine Albert anticipates.

Results of the VANISH-2 trial, building on prior research, further upheld superiority of catheter ablation over ...

His autopsy report, published in the New England Journal of Medicine, noted that DeMar’s left main coronary artery contained ...

The original system included two different revascularization options ... is considered the standard of care in patients with acute ischemic stroke presenting within 4.5 h after onset.

The incidence of target-lesion revascularization was 6.5, 9.0, and 10.2% at 6, 12 and 24 months, respectively. The MELODIE trial also demonstrated the safety of iliac artery revascularization with ...

Our expert staff answers frequently asked questions in their areas of expertise and defines common terms so you can be a smarter shopper. Read more here. I started getting emails about salmon ...

claiming a green light from the US regulator for mavacamten as a therapy for obstructive hypertrophic cardiomyopathy (HCM). Orally-active mavacamten – which was acquired by BMS when it bought ...

Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...

The adult human heart contains small numbers of cardiac stem cells that are able to partially repair the heart following a heart attack or throughout the course of progressive heart failure. We have ...

OBJECTIVE: Myocardial perfusion scintigraphy is a common non-invasive method for assessing ischemic burden ... Patients with acute coronary syndrome, a history of revascularization (stent and bypass), ...